Literature DB >> 2737798

Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid.

A H Staib1, S Harder, U Fuhr, C Wack.   

Abstract

The single-dose pharmacokinetics of theophylline alone and at the end of a five-day treatment period with a new difluorinated quinolone antibacterial, lomefloxacin (400 mg/d) and pipemidic acid (400 mg b.i.d.) were investigated in 12 healthy male volunteers. Concentration of theophylline and its metabolites 1-methylxanthine, 1-methyluric acid, 1.3-dimethyluric acid and 3-methylxanthine were determined in plasma, and (except 1-methyluric acid) in urine by HPLC separation. The elimination half-life of theophylline before quinolone treatment was 5.7 +/- 2.0 h and did not change significantly under coadministration of lomefloxacin (6.2 +/- 2.0 h), whereas with pipemidic acid a marked prolongation (10.8 +/- 2.3 h) occurred. Results without and during coadministration of lomefloxacin showed no detectable 1-methylxanthine in plasma. With pipemidic acid, 1-methylxanthine was observed in the plasma and 1-methyluric acid and 3-methylxanthine were not detected. Lomefloxacin showed only a slight alteration in the metabolite formation of theophylline, whereas pipemidic acid induced marked changes. In contrast to pipemidic acid, no metabolic interaction would be expected under concomitant use of lomefloxacin and theophylline within the recommended dose range for both drugs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2737798

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  12 in total

1.  Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics.

Authors:  F Sörgel; G Mahr; G R Granneman; U Stephan; P Nickel; P Muth
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

Review 2.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

3.  Influence of lomefloxacin on the pharmacokinetics of theophylline.

Authors:  M LeBel; F Vallée; M St-Laurent
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 4.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

5.  Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.

Authors:  M Parent; M St-Laurent; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Lack of interaction between lomefloxacin and caffeine in normal volunteers.

Authors:  D P Healy; J R Schoenle; J Stotka; R E Polk
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

7.  Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state.

Authors:  M Kinzig-Schippers; U Fuhr; M Cesana; C Müller; A H Staib; S Rietbrock; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 8.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

9.  Structure-related inhibitory effect of antimicrobial enoxacin and derivatives on theophylline metabolism by rat liver microsomes.

Authors:  Y Mizuki; I Fujiwara; T Yamaguchi; Y Sekine
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 10.  Lomefloxacin clinical pharmacokinetics.

Authors:  C D Freeman; D P Nicolau; P P Belliveau; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.